Posted from: Tuesday, September 05, 2017 - 04:16 PM - Present

Generic Launched for Transderm Scop

July 31, 2017 – Perrigo has launched an AB-rated generic for Transderm Scop® (scopolamine) 1.5mg patches, which are indicated to prevent nausea and vomiting induced by motion or surgery. To prevent motion sickness, a single patch should be placed on clean, dry, hairless skin behind one ear, and should be worn for three days. To prevent vomiting in patients who are undergoing surgical procedures, a single patch should be adhered behind the ear the evening before scheduled surgery, and should be worn for 24 hours following surgery. Sales for Transderm Scop in the 12 months ending on May 31, 2017, were estimated at $158 million. Perrigo has not yet announced pricing for the generic.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Monday, November 20, 2017 - 03:07 PM.